RecruitingMajor Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Eligible age
18+ yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Sponsor: Neurocrine Biosciences
Where it's recruiting
Arkansas
Little Rock
California
Garden Grove · Orange · Pico Rivera · San Diego …
Florida
Hollywood · Maitland
Massachusetts
Boston · Watertown
New York
Mount Kisco
Ohio
Avon Lake · Westlake
Texas
Dallas · Houston · Richmond · The Woodlands
Washington
Everett
Source: ClinicalTrials.gov · NCT06786624 · last updated 2025-10-29